| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $1,485,743 | 5 | 45 |
Sells | $58,976,676 | 6 | 55 |
| TANG KEVIN | 10 percent owner | 5 | $1.49M | 0 | $0 | $1.49M |
| Oltmans Curtis Gale | Chief Legal Officer | 0 | $0 | 1 | $44,600 | $-44,600 |
| Ezekowitz Alan | director | 0 | $0 | 1 | $65,614 | $-65,614 |
| Gould Robert J | director | 0 | $0 | 3 | $489,441 | $-489,441 |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 0 | $0 | 1 | $58.38M | $-58.38M |
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in …
Over the last 12 months, insiders at Fulcrum Therapeutics, Inc. have bought $1.49M and sold $58.98M worth of Fulcrum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fulcrum Therapeutics, Inc. have bought $13.99M and sold $12.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: TANG KEVIN (10 percent owner) — $1.49M.
The last purchase of 50,945 shares for transaction amount of $179,326 was made by TANG KEVIN (10 percent owner) on 2026‑07‑17.
| 2026-07-17 | TANG KEVIN | 10 percent owner | 50,945 0.0908% | $3.52 | $179,326 | +2.74% | ||
| 2026-07-16 | TANG KEVIN | 10 percent owner | 116,671 0.2193% | $3.56 | $415,349 | +7.14% | ||
| 2026-07-15 | TANG KEVIN | 10 percent owner | 107,377 0.1968% | $3.56 | $382,262 | +5.20% | ||
| 2026-07-14 | TANG KEVIN | 10 percent owner | 129,603 0.2383% | $3.57 | $462,906 | +4.18% | ||
| 2026-07-13 | TANG KEVIN | 10 percent owner | 12,966 0.024% | $3.54 | $45,900 | +5.65% | ||
| 2026-06-26 | Sale | Ezekowitz Alan | director | 18,000 0.0319% | $3.65 | $65,614 | -1.84% | |
| 2026-02-02 | Sale | Gould Robert J | director | 15,000 0.0277% | $10.72 | $160,857 | -64.13% | |
| 2026-01-02 | Sale | Gould Robert J | director | 15,000 0.0266% | $10.87 | $163,089 | -64.47% | |
| 2025-12-15 | Sale | Oltmans Curtis Gale | Chief Legal Officer | 3,452 0.0064% | $12.92 | $44,600 | -50.58% | |
| 2025-12-08 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 4.18M 8.3051% | $13.98 | $58.38M | -49.35% | |
| 2025-11-19 | Sale | Gould Robert J | director | 15,000 0.0266% | $11.03 | $165,495 | -41.18% | |
| 2025-05-08 | Sale | Tourangeau Greg | Principal Accounting Officer | 498 0.0009% | $5.06 | $2,520 | +45.47% | |
| 2024-05-07 | Sale | Tourangeau Greg | Principal Accounting Officer | 236 0.0004% | $7.76 | $1,831 | -47.02% | |
| 2024-03-08 | Sale | Tourangeau Greg | Vice President, Finance | 4,884 0.0084% | $11.72 | $57,219 | -44.40% | |
| 2024-03-04 | Sapir Alex | See Remarks | 43,360 0.0707% | $11.35 | $492,028 | -44.92% | ||
| 2023-05-10 | Sale | Tourangeau Greg | Principal Accounting Officer | 210 0.0004% | $3.31 | $695 | +46.48% | |
| 2023-01-20 | RA CAPITAL MANAGEMENT, L.P. | director | 1.92M 3.8009% | $13.00 | $25M | -68.65% | ||
| 2023-01-13 | Sale | Gould Robert J | Interim President & CEO | 6,766 0.0142% | $15.00 | $101,490 | -71.09% | |
| 2023-01-04 | RA CAPITAL MANAGEMENT, L.P. | director | 180,703 0.3049% | $7.28 | $1.31M | -52.17% | ||
| 2022-12-27 | RA CAPITAL MANAGEMENT, L.P. | director | 4,089 0.009% | $5.99 | $24,510 | -34.44% |
| TANG KEVIN | 10 percent owner | 7080945 9.2807% | $26.48M | 5 | 0 | |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 6053960 7.9347% | $22.64M | 7 | 1 | |
| Oltmans Curtis Gale | Chief Legal Officer | 10252 0.0134% | $38,342.48 | 1 | 1 | +68.04% |
| LEVIN MARK J | 5962202 7.8144% | $22.3M | 1 | 0 | +2.11% | |
| Third Rock Ventures III, L.P. | 10 percent owner | 5962202 7.8144% | $22.3M | 1 | 0 | +2.11% |
| Third Rock Ventures IV, L.P. | 10 percent owner | 2343154 3.0711% | $8.76M | 1 | 0 | +2.11% |
| Casdin Capital, LLC | 10 percent owner | 604285 0.792% | $2.26M | 1 | 0 | +2.11% |
| 6 Dimensions Capital, L.P. | 10 percent owner | 559821 0.7337% | $2.09M | 1 | 0 | +2.11% |
| Sanofi | 10 percent owner | 558035 0.7314% | $2.09M | 1 | 0 | +2.11% |
| GERAGHTY JAMES A | director | 90714 0.1189% | $339,270.36 | 1 | 0 | +68.04% |
| Sapir Alex | See Remarks | 43360 0.0568% | $162,166.40 | 1 | 0 | |
| Thomson Peter G. | VP Finance & Accounting | 2300 0.003% | $8,602.00 | 1 | 5 | +68.04% |
| Morabito Christopher | Chief Medical Officer | 1100 0.0014% | $4,114.00 | 1 | 0 | +68.04% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$104,171,521 | 16 | 20.21% | $275.53M |
| Increased Positions | 103 | +66.88% | 23M | +43.09% |
| Decreased Positions | 67 | -43.51% | 10M | -18.1% |
| New Positions | 60 | New | 13M | New |
| Sold Out Positions | 19 | Sold Out | 881,636 | Sold Out |
| Total Postitions | 190 | +23.38% | 67M | +24.99% |
| Ra Capital Management, L.P. | $111,702.00 | 15.5% | 10.23M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $58,761.00 | 8.15% | 5.38M | +298,100 | +5.87% | 2025-09-30 |
| Tcg Crossover Management, Llc | $57,330.00 | 7.96% | 5.25M | 0 | 0% | 2025-09-30 |
| Nantahala Capital Management, Llc | $51,005.00 | 7.08% | 4.67M | +382,485 | +8.92% | 2025-09-30 |
| Blackrock, Inc. | $40,478.00 | 5.62% | 3.71M | -672,273 | -15.35% | 2025-09-30 |
| Vanguard Group Inc | $32,754.00 | 4.55% | 3M | -146,979 | -4.67% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $26,557.00 | 3.69% | 2.43M | -2M | -47% | 2025-09-30 |
| Balyasny Asset Management L.P. | $15,839.00 | 2.2% | 1.45M | +112,266 | +8.39% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $15,828.00 | 2.2% | 1.45M | +272,712 | +23.18% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $14,188.00 | 1.97% | 1.3M | -73,329 | -5.34% | 2025-09-30 |